

# Index

Abbreviations after page numbers: ac=acknowledgments and citations; ap=appendix; b=boxed comments; f=figure; fr=further reading; t=table.

- accuracy, 71-85, 95-6
- ACTH, 59-60, 175ap
- Adams, R.M., 77b
- Allen, F.H. Jr., 21t, 186ac
- allotment, 46-54, 162-3
- arithmetic, valid, 80, 81b
  - see also* measurement, scales of
- Asher, R., 75-6, 94b, 188ac
- Ashton, N., 176ap
- assignments of treatments (non-random), 54-6
- authoritarianism, 1-2
  
- Bacon, Francis, 3-6
- Banta, H.D., 182fr
- Bayes, Reverend Thomas, 135-6b, 147
- belief, 137, 139
- Bell, Joseph, 72b, 73
- benefit, 145-6b, 162-3
- Berkeley, Bishop George, 88b
- Bernard, Claude
  - doubt and refrain maxim, 150
  - on experimental methods, 7
  - on levels of observation, 15
  - on physicians, 7-8
  - treatise on experimental medicine, 7, 183fr
- Bessel, 82
- bias
  - Berkson's, 34b, 35
  - in experimentation, 27, 103-4
  - confirmation, 82
  - labeling, 78
  - of observer, 76
  - personal, 54
  - procedural, 69-70, 109
  - Sackett's lists of, 34b, 68b
  - systematic, 127
  - trial size and, 132
  - see also* experimenters' effects; measurement; sampling
- Bibbo, M., 38, 187ac
- Bills of Mortality, 24-6b
- binomial distribution, 32-3b
- birth weight
  - distribution of, 35-7
  - RLF and, 35t, 36f, 51f
- blind, precaution in studies, 62-3
- blindness, *see* RLF
- blocks, allotment in, 49b
- blood
  - exsanguination, 153, 154b
  - transfusion, 21
  - see also* oxygen, in blood; RLF, blood transfusion and
- Boston, *see* RLF, Boston survey; surgical treatment, for prevention of hemorrhage
- brain damage, *see* neurologic outcome
- Braunwald, E., ix, 185ac
- bridge hands (card game), 19-20
- Bronowski, Jacob, 27, 186ac
- Burnet, M., vii, 185ac
- Bull, J.P., 183fr
- Busenbaum, 169
- Byar, D.P., 50, 187ac
  
- Campbell, K., 18, 19t, 175ap, 186ac
- cancer
  - experiment scandal, 157
  - after DES, 38t
  - deaths in treatment trials in, 163
  - duration of observation in, 101

- cancer—*cont.*  
 hypothetical trials in, 103–4  
 Research Centre (London), 184fr  
 surgical treatment of, 58f
- cannon ball hits, 19b
- Card, W.I., 115f, 143, 144f, 183fr
- Cardon, P.V., 191ac
- Cardano, Giralomo, 140f, 190ac
- Cassileth, B.R., 164, 167, 191ac
- causation  
 Bayes' approach to, 135–6b  
 concepts of, 23b, 24b  
 Galton's insight and, 23b  
 'cause' (goal), identification with, 165
- cerebral palsy, *see* neurologic outcome
- Chalmers, I., 185ac
- Chalmers, T.C.  
 on impact of trials, 168  
 influence of, 12  
 proposal of, 52, 188ac  
 on trial design, 180ap, 192ac
- chance *see* logic of chance; statistical reasoning
- Chandler, P.A., 173
- children, 166–7  
*see also* infants
- cholera, 9b
- Clark, C.J., 117f, 118f, 190ac
- Clifford, S.H., 173ap
- clinical trials, *see* multicenter trials;  
 randomized clinical trial format;  
 trials
- Clinical Trials Centre (London), 184fr
- codes of ethics 155, 156b
- coin-tossing, 27–8, 123, 134
- co-intervention bias, 68b, 69
- collaborative studies, *see* multicenter trials
- Commission for the Protection ..., 164, 166, 191ac
- Community and medicine (institution)  
 a 'defined good', 88, 170  
 re human experimentation  
 alienation, 168–9  
 attitudes, 163  
 justification of research, 159  
 pace of innovation, 149–50  
 polio trials, 66  
 poor information about, 8–9  
 re 'important difference', 120–21  
 re informed consent, *see* consent, informed
- re research questions, 159
- compliance, 104, 105f, 168
- Comroe, J.H., Jr., 158, 191ac
- confidence intervals (limits)  
 in sampling experiment, 32–3b  
 in trial results, 130–31
- confirmation bias, 82
- confoundment, *see* entrapment
- conscription for trials, 165
- consent, informed  
 communal, 166  
 disavowal of, 168  
 discretionary, 167–8  
 freely given, 165–9  
 patient's attitudes and, 167–8  
 by surrogates, 166–7  
 surveillance, informed, 167  
 useless study and, 165b
- consequences, weighing, 147
- consistency of observations, 84
- contamination bias, 68b, 69–70, 109
- Controlled Clinical Trials* (journal), 182fr
- controls  
 concurrent, need for, 44, 46  
 'historical', 42–6  
 lack of, 53f  
*see also* randomized clinical trial format; trials
- cooperative studies, *see* multicenter trials
- correlation, Galton's insight, 23b
- cost benefit evaluation, 145–6b
- critical rationalism, ix
- crossover design, 67b, 68
- Crosse, M., 175ap
- Crusoe, Robinson, parable of, 171
- Cusum plotting method, 93b
- Cuvier, Georges, 6b
- Darlington, R.B., 134, 135, 137, 183fr
- data analysis  
 badgering, 129  
 dredging, 20–22, 99, 109  
 in Boston survey, 16  
 in national RLF trial, 60–61
- David, F.N., 47b, 186ac
- Day, R.L., v, 185ac
- death, as outcome measure, 86–8, 98–9, 122t  
*see also* Hippocrates; mortality
- decision analysis, 142–8
- benefits and costs format, 145–6b
- definition of terms in, 143b
- formulation of decision problem, 142b
- medical decision model, 144f
- decisions  
 in diagnostic process, 143–6  
 sequential, 150  
 terminal, 149  
 weighing consequences of, 147
- Democratic ideals, viii, 56, 165
- demography, *see* birth weight, distribution of; pregnancy, high risk
- DES (diethylstilbestrol), 38t
- developing countries, trials in, 166, 169
- diagnosis  
 accuracy in, 73, 95–6  
 decision model for, 143–6  
 discrimination in, 95  
 in highly fatal conditions, 114  
 probability model of, 115f
- dice games, 41, 139–41
- disease, *see* illness; mortality; *specific disorders*
- dissent, informed, 168
- divination by lots, 47b, 48
- Dobson, Matthew, 72b
- doctors, *see* physicians
- Doyle, Arthur Conan, 72b, 73, 74f
- draft by lottery, 164
- Drake, S., 5
- drugs  
 certification of, 150–51  
 development of slowed, 151  
 dosage of, 52, 59–62  
 nihilism era, 153  
 phases of evaluation, 151b  
 17th century drugging, 154b
- 'dummy', 67
- Dworkin, R., 160–61, 183fr
- eclipse, 'treatment' of, 1
- Ehrlich, Paul, 153
- Eisenberg, L., 163, 191ac
- end point, *see* outcome
- ends and means doctrine, 169–70
- England, *see* United Kingdom
- enthusiasm, in trials, 53f
- entrapment  
 compliance related, 104, 105f  
 prognosis related, 103–4
- time related, 100–103
- error  
 fruitful, 171b  
 observer, 81–2, 92, 94  
 random, 127
- Type I  
 multiple look and, 124–5  
 0.05 level of, 128  
 publishing and, 132–3  
 in subclasses, 133  
 trial size and, 119, 130–32
- Type II, 119  
*see also* measurement
- erythroblastosis, 21
- ethics  
 codes of, 155, 156b  
 design of study and, 165b  
 human experiments and, 153–72  
 limits to discovery, 159  
 moral judgment, 170b  
 obligation to test, viii  
 placebos and, 66–7  
 random allotment and, 162–3  
*see also* consent, informed; values ...
- 'Evangelists', 149
- events of interest, *see* outcome
- evidence  
 decisive amount of, 127–8  
 quality of, 163  
 rules of and hardship, 8  
 Sherlock Holmes and, 73  
*see also* measurement; observations
- exclusions in trials, 107–8
- expectancy phenomenon, 64–6
- experimentation, human  
 antipathy to, viii, 154  
 and democratic principles, viii, 56, 165  
 goals of, 158–9  
 in Nazi Germany, 155  
 scandals, 157  
 self-regulation and, 157  
 spirit of, 161  
*see also* randomized clinical trial ...; trials
- experimenters' effects, 63–6  
 expectancy phenomenon, 64–6  
 in measurement, 81–5  
 Pygmalion experiment, 65b  
 in treatments, 66  
*see also* 'masking', in trials; placebos

- experiments (method of study)  
 Baconian, 5-6  
 Bernard on, 7  
 definition of, 54b  
 demonstrative, 5  
 Galilean, 5-6, 7  
 phases of, 7  
 pros and cons of, 12b  
 quasi-experimental, 54b  
*see also* statistical reasoning  
 explanatory trials, 29, 30
- failure (trial outcome), index of, 109  
 favorable circumstances, enumeration of fallacy, 99
- Feinstein, A.R.  
 book of, 182fr  
 influence of, 11  
 on life-tables, 92  
 on randomization, 52  
 on unequal groups, 103-4, 105f
- Fermat, Pierre de, 139
- Fielding, L.P., 58f, 188ac
- Fisher, R.A.  
 pioneering work of, 10-11b  
 on randomization, 11b, 50, 186ac  
 on repeated demonstrations, 148, 191ac  
 on 'significance' level, 128  
 textbook of, 187ac
- 'fishing', 20  
*see also* data analysis, dredging
- flotation controversy, 5b
- follow-up, 86-8, 99, 177-8ap
- Food and Drug Administration (FDA), 151b
- forecasting, *see* prediction
- Fredrickson, D.S., 13, 186ac
- Freidson, E., 170, 183fr
- Freiman, J.A., 119, 190ac
- Galbraith, J.K., 9, 185ac
- Galen, 1-2, 8, 15
- Galileo, 5-6, 139
- Galton, Francis, 23b, 186ac
- gambling  
 forecasting in, 27-8  
 gamblers, 139-41  
 wagers in, 129, 138, 150  
*see also* specific games
- Gardner, M., 73
- Gilbert, J.P., 53f, 88, 162-3, 188ac
- glossary, in trials, 95
- goals, *see* 'cause' ...; community ...; medicine ...; social impact
- Goffman, E., ix, 185ac
- Gossett, W.S., 11
- Grace, N.D., 188ac
- Greenwood, M., 26b, 186ac
- Gregory, G.A., 189ac
- Guardians, 166-7
- Haggard, H.W., 154b, 191ac
- handicaps, *see* RLF; neurologic outcome
- Hardwick, M., 72b, 188ac
- Harvey, William, 2, 6
- Helsinki, Codes of Ethics, 155, 156b
- hidden man figures, 75f, 76f
- Hill, A. Bradford, 11, 186ac, 189ac
- Hippocrates, 71, 89, 153
- Hoeck, L., 176ap
- Holmes, Oliver Wendell  
 elder (physician), 153  
 younger (jurist), 13b, 157
- Holmes, Sherlock, 72b, 73
- horse racing, 124
- hospitals  
 admission, causes for, 35, 39, 41  
 birth weight distribution, 35-7  
 in Melbourne, 18-19  
 review committees, 158  
 RLF surveys of, 16-19, 35t  
 stratification by, 51  
 studies in, 35, 101-3  
 types of, 35, 39
- Hudson, J., 132b, 190ac
- 'hunting', 21  
*see also* data analysis, dredging
- Huxley, T.H., 147b
- Hypotheses  
 belief state and, 137  
 formation of, 15  
 null, 116  
 refutability of, 15, 19  
 test of, 116, 190ac  
*see also* observations; questions
- illness  
 course of, 100-101  
 shifting severity of, 42-4, 114
- indicants, 143-6
- inductive reasoning  
 of Bacon, 3

- of Bayes, 135-6b
- infants  
 mortality of, 45, 62, 101  
 newborn, viii, 45-6  
 strawberry marks in, 102-3  
*see also* children; infections; intensive care ...; mortality; oxygen; positive pressure ...; RLF
- infections  
 in ACTH treatment, 59, 175ap  
 treatment for, 45-6
- inference, *see* statistical reasoning
- informing, *see* consent, informed
- injury, in trials, 169
- innovations, *see* interventions
- Instauratio Magna*, 3, 4f
- intensive care, results of, 86-8, 99
- Interval, measurement scale, 80  
*see also* time, durations of
- interventions, 57-70  
 bona fide, 59-60  
 conflicting effects of, 45-6  
 harmful potential of, viii-ix  
 multiple, 67-9  
 policy of, 30  
 specification of, 57-62  
 success rate of, 162f  
*see also* multicenter trials; trials, variability, in interventions; specific treatments
- iron treatment, *see* RLF, iron administration and
- Johnson, Lyndon, 'doctrine', 149
- Jonas, H., 165, 191ac
- Katz, J., 155, 191ac
- Kefauver-Harris Amendment, 150
- Kenny, Sister, treatments of, 66
- Kernicterus, 46
- Kinnebrook, 81-2
- Kinsey, V.E., 16, 17f, 186ac, 187ac
- Kitchen, W.H., 87, 189ac
- Klimt, C.R., 110b, 189ac
- Kurman, P., 186ac
- Labeling bias, 78
- Lanman, J.T., 190ac
- Lavoisier, Antoine, 97b
- laws of chance, *see* gambling; probability
- Leombruno, 47f, 187ac
- Levine, R.J., 182fr
- Levinson, H.C., 19b, 186ac
- life  
 length of, 100-101  
 life-table format, 90-91b, 91-2  
 quality of, 88-9  
*see also* outcome, survival as
- Lind, James, 7b, 185ac
- logic of chance, 183fr  
*see also* gambling; probability
- losses (poor outcome), 150  
*see also* trials, lost to follow-up
- Louis, Pierre ..., 153
- McDonald, A.D., 61f, 178ap, 188ac
- McKeown, T., 43, 187ac
- MacLeish, Archibald, 29b
- McPherson, K., 124-5, 190ac
- Mahler, H., 149, 191ac
- Mainland, Donald  
 on Bayes' approach, 135-6b, 190ac  
 influence of, 11  
 on precautions in trials, 104-5, 189ac  
 on replication, 148, 191ac  
 sampling experiment by, 32-3b, 187ac  
 on 'significance', 127-8, 190ac  
 textbook of, 187ac
- 'markers' (patient), 39-41
- Maskelyne, 81-2
- 'masking', in trials, 62-3  
*see also* placebos
- measure  
 in astronomy, 81-2  
 accuracy in, 81-5  
 fiber of modern medicine, 85  
 observer error, 81-2, 92, 94  
 'personal equation' in, 82  
 scales of, 77-80  
 sets of, 82-4
- Medawar, P.B., 6, 183fr
- medical profession, *see* physicians
- medical treatment (in general)  
 custom and, 163  
 nihilism and, 153  
 17th century excesses of, 154b  
 as weaponry, 8, 150, 168  
*see also* drugs; interventions
- medicine (institution of)  
 character of, 161, 169  
 criticism of, 7-8, 153-4, 170  
 goals of, vii

## medicine—cont.

- human affairs and, 170
- privileged position of, 159
- Méré, the Chevalier de, 139
- millenarianism, 3
- Mills, C. Wright, 170b
- morals, *see* ethics
- Morris, N.M., 45, 187ac
- mortality
  - adjusted rates of, 101
  - highly fatal disorders, 44, 114
  - infant, 45, 62, 101, 178ap
  - London Bills of, 24–6b
  - neonatal, 62, 101, 178ap
  - scarlet fever trend in, 43
  - tuberculosis trend in, 43–4
  - see also* death; outcome; oxygen
- Muench, Hugo, 53f, 70
- multicenter trials
  - coordination center for, 110–11
  - need for, 120
  - of oxygen and RLF, 176–7ap
  - birth weights in, 39, 51f
  - dosage in, 60–61
  - monitoring in, 57–8
  - over-interpretation of, 178ap
  - survival in, 98
  - target events in, 96–7, 134–5
  - wide population base of, 37
  - of streptomycin and tuberculosis, 11, 37, 43–4
  - of sulfinpyrazone, after heart attack, 123
  - of surgical treatment, for bowel cancer, 58f
  - see also* trials
- multiple look issue, 122–6
  - see also* 'significance'
- Mumford, Lewis, 152, 191ac
- Murphy, E.A., 33, 100b, 183fr
- National Commission for the Protection . . . , 164, 166, 191ac
- National Institutes of Health, 158, 163
- National Perinatal Epidemiology Unit (Oxford), 183–4fr
- national trial of RLF, *see* multicenter trials, of oxygen and RLF
- neurologic outcome
  - after intensive care, 87
  - oxygen policy and, 61f, 62, 178ap
  - RLF and, 61f

- nominal measurement scale, 77–8
- nonparametric tests, 129
- 'not proven' verdict, 137
- Novum Organum*, 3
- null hypothesis, 116
- nurses, resistance of, 107

observational method of study, *viii*, 2, 7

- pros and cons of, 12b
- observations
  - accuracy of, 71–85
  - 'active', 15, 16, 98
  - consistency of, 84
  - duration of, 101–3
  - observer error in, 81–2, 92, 94
  - 'passive', 15–16
  - pattern recognition, 73
  - precision of, 84–5, 92–5
  - pre-figured, 75–6
  - question seeking, 15–22
  - reliability of, 84
  - reproducibility of, 92–5
  - standardization of, 94–5
  - theory-impregnated, 73
  - unbiased, 84
  - validity of, 85
  - variation between observers, 94
  - see also* measurement; variability
- Odell, G.B., 46, 187ac
- ordeal, of experiment, 6, 13
- ordinal measurement scale, 79–80
- Owens, W.C., 174ap
- outcome, 86–9
  - confirmation of, 62, 92–6
  - conflicting, 88, 121–2
  - estimation of difference in, 113
  - failure index of, 109
  - handicap as, 87f, 99
  - 'important difference' in, 119, 120–21
  - life-table of, 90–91b, 91–2
  - long term, 89
  - multiple end points, 121–2
  - neurologic, *see* neurologic outcome
  - surrogate, 86–9
  - survival as, 86–8, 98–9, 122
  - target events, 96–9
  - unpredicted, 99
  - variability of, 97f
  - see also* multiple look issue; mortality; oxygen, survival and; utility

## oxygen

- in blood, 179ap
- and cerebral palsy, 61f, 62, 178ap
- concentration of, 57–8, 130, 177ap
- in determinative era, 179ap
- in incubators, 175ap
- hyaline membrane disease and, 113–34, 178ap
- respirations and, 55, 60
- in restriction era, 178ap
- and RLF, 175–7ap
  - association, *viii*, 16–17, 22–4, 26, 135–6b
  - multicenter trial of, 37, 57–8, 60–62
  - single hospital trial of, 107, 121–2, 130, 176ap
  - and strawberry marks, 102
  - survival and, 60–62, 98–9, 177ap, 178ap
  - withdrawal of, 175ap
- P value, 130
  - see also* Error, Type I
- parametric tests, 129
- parents, 166–7
- Pascal, Blaise, 139
- patients
  - attitudes of, 63–4, 164
  - 'available', 33–5, 45, 120
  - choices of action of, 33, 150
  - classes, 35–7, 39–41, 77–8
  - compliance of, 104, 105f, 168
  - excluded (in trials), 107–8
  - lost to follow-up, 108f, 109
  - recruitment of, 41, 164–5
  - representative, 30–41, 165
  - rights of, 160, 168
  - number required, 117f, 118f
  - social level of, 166
  - uncooperative, 104, 105f, 168
  - veto options of, 167, 168
  - withdrawn (in trials), 108
  - see also* consent, informed; risk; risk and benefit; trials, volunteering for
- pattern recognition, 73
- Patz, A., 176ap
- Pauker, S.G., 146b, 191ac
- Pearson, Karl, 11, 128, 186ac
- 'peeking', 123–4, 125t
- perception, appearance and reality, 88b
- 'permission' versus 'consent', 166

- 'personal equation' in measurement, 82
- Peto, R.
  - on trial design, 59, 182fr
  - on trial irregularities, 108f, 109
  - on trial size, 131
- Petty, William, 26b
- physicians
  - alienation of, 168
  - attitudes of, 105–6
  - authority of, 159, 170
  - behavior of, 35, 54, 63, 169
  - criticism of, 7–8, 170
  - decision analysis and, 147–8
  - as detectives, 72b, 73
  - as gamblers, 28, 129
  - good intentions of, 170
  - invulnerability claims of, 1–2
  - personal, 167
  - practising, 168
  - public trust in, 170
  - and research results, 168
  - resistance to experimental method, 7
  - roles of, 110, 150
  - social level of, 166
  - value judgments of, 147, 170
  - veto options of, 167
  - see also* medicine, institution of
- pilot trials
  - randomization in, 52
  - size of, 112–16
  - uncontrolled, 52–3
  - see also* trials
- placebos, 66–7
  - see also* 'masking', in trials
- play the winner trial design, 55
- policy
  - definition in rights thesis, 160b
  - of treatment, 30
- poliomyelitis, 66, 158, 165
- Popper, Karl R.
  - on criticism, 172
  - on errors, 172
  - essays of, 182fr
  - objections to induction, 6
  - on observation, 73
  - on refutability, 15, 19
  - Robinson Crusoe, parable of, 171
  - on scientific objectivity, 171
- population, parent or target, 31, 33, 35, 37
  - distribution of variables in, 129
  - see also* patients; sampling

- positive pressure treatment, 113-14,  
115, 122, 145-6b  
Postman, N., 14, 186ac  
power of the test, 119  
pragmatic trials, 29, 30, 109, 116, 137  
precision of observations, 84-5, 92-5  
prediction  
  in gambling, 20, 27-8  
  in medicine, 18, 22-3, 28, 76-7, 141-2  
pregnancy  
  DES in, 38t  
  high risk, 45  
  prenatal care in, 45  
  thalidomide in, 150  
premature infants, *see* infants  
principle (of human rights)  
  definition of, 160b  
  right to health as, 159-60  
probability  
  binomial distribution, 32-3b  
  conditional, 135b  
  of diagnosis, 115f  
  direct, 134-5  
  equiprobability, 28, 141  
  impossibility and, 18  
  improbable events, occurrence of, 18  
  inverse, 134-5  
  misunderstanding about, 19b  
  P value, 130  
  prior, 135-6b  
  samples, 33  
  state of nature and, 139, 141  
  surprise and, 17-20  
  subjective (personal), 136b  
  theory of, defined, 139  
  *see also* decision analysis; gambling;  
  'significance'  
probable trend concept, 27  
professions, goals of, 170  
prognosis  
  indicators of, 50-51  
  traps related to, 103-4  
proof concept, 134-8  
proportional propositions, 28  
proxy outcome events, 86-9  
Public Health Service (U.S.)  
  prior review requirement of, 157-8  
  syphilis study scandal, 157  
public interest, *see* community ...  
publication decisions, 21, 132-3  
Pygmalion experiment, 65b  
quasi-experiments, 54b  
questions, 14-29  
  and answers, 29  
  distraction-resistant, 29  
  genuine, 15  
  meaningful, 28-9  
  number-specific, 22, 115  
  origins of, 15-22  
  proportional propositions, 28  
  pseudo, 15  
  realistic, 107  
  restrictions on, 159  
  weak, 22, 115  
  *see also* hypotheses  
Rabi, I.I., 159, 191ac  
Raiffa, H., 142b, 146, 190ac  
random  
  allotment, 46-54, 162-3  
  'balanced' sequences, 49b  
  definition of, 31  
  error, 127  
  frequency test, 128  
  numbers, 49b  
  randomness, 27, 31, 141  
  sampling, 30-31, 32-3b  
randomized clinical trial format  
  check list for, 180-81ap  
  democratic ideals and, *viii*, 56, 165  
  evolution of, *vii*, 11-13  
  limitations of, 12b  
  opposition to, *viii*, 163  
  predictive function of, 146  
  size of, 97-8, 112-26, 130-32  
  *see also* pilot trials; trials  
rarity, *see* probability; 'significance'  
ratio measurement scale, 80  
rationality, principle of, 143b, 147  
reasoning, *see* inductive reasoning;  
  statistical reasoning  
refutability, 15, 19  
Reid, D., 70  
relative frequency, *see* probability  
reliability of observations, 84  
religion  
  medicine's roots in, 169  
  pursuit of knowledge and, 3  
reparation for injury, 169  
replication, *see* measurement,  
  replication of; trials, replication of  
representativeness, 30-41  
  external relevance and, 33

- in polio trials, 165  
  *see also* sampling  
reproducibility of observations, 92-5  
research  
  in agriculture, 10-11b, 26  
  basic biomedical, 158-9  
  goal directed, 158, 159  
  guidelines (FDA), 151b  
  'purposeless', 158  
  questions in, 14-29  
  *see also* experiments; trials  
respirations, oxygen and, 55, 60  
retrolental fibroplasia, *see* RLF  
review committees, 158  
review, prior, 157-8  
rights  
  abstract, 160  
  concrete, 160-61  
  of dissent, 168  
  of health, 159-60  
risks, *see* trials, risk in; trials, risk  
  limitation in  
risk and benefit evaluation, 162-3  
  'significance' level and, 130  
  *see also* decision analysis, benefits  
  and costs format  
RLF  
  ACTH and, 59-60, 175ap  
  in animals, 61, 176ap  
  birth weight and, 35t, 36f, 51f  
  blood transfusions and, 18  
  Boston survey of, 16-17, 18, 19,  
  174ap  
  'causes' of, speculated, 174ap  
  in cities, 35t, 173ap  
  congenital, 24b  
  follow-up of, 177-8ap  
  in hospitals, 16-19, 35t  
  important difference in frequency,  
  121  
  incubators and, 175ap  
  iron administration and, 16-17,  
  174ap  
  in Melbourne, 18-19, 22, 135b,  
  175ap  
  national trial, *see* multicenter trials,  
  of oxygen  
  oxygen and, *see* oxygen, and RLF  
  resurgence of, 179ap  
  retrospective surveys of, 35t, 173ap  
  stages of, 79  
  story of, *viii*, 173-9ap

- and strawberry marks, 102  
  and survival, 122t  
  twins and, 77  
  in the US (general), 174ap, 176ap  
  vitamins and, 16-17, 174-5ap  
  without oxygen treatment, 24b, 178ap  
Rosenthal, R., 64f, 65b, 188ac  
roulette, 99  
Rumpelstiltskin effect, 94b  
Rutstein, David, 165b  
Sackett D.L.  
  on biases, 34b, 68b, 187ac  
  influence of, 12  
  on pace of innovation, 149, 191ac  
  on reading journals, 183fr  
sample size graphs, 117f, 118f  
sampling  
  assumptions in, 31  
  in clinical studies, 33-8  
  haphazard, 33  
  random, 30-31, 32-3b  
scales of measurement, 77-80  
scarlet fever, 43  
scandals, 157  
Schneiderman, M.A., 42, 187ac  
Schwartz, D., 30, 182fr  
science  
  advances in, 158-9  
  criticism in, *ix*, 8  
  freedom of inquiry in, 158-9  
  method, basic tenet of, 18  
  objectivity of, 171  
  rules of evidence, hardship and, 8  
  social aspect of, 171-2  
  values of, 159  
  *see also* Popper, Karl R.  
scores, for signs and symptoms, 79-80  
scurvy, 7b  
Selvin, H.C., 20, 186ac  
semiology, medical, 71  
sensitivity  
  of a test, 95b  
  of trials, 50  
Sequential analysis, 125  
  *see also* multiple look issue  
sham procedure, 66  
Shapiro, A.R., 141-2, 190ac  
Sigerist, Henry E., 161b, 191ac  
'significance'  
  belief and, 137  
  confusion about, 127-8

- 'significance'—*cont.*  
 declaration of, 10b, 119, 123–5, 127–8  
 as direct probability, 134–5  
 Fisher's view of, 128  
 level, choosing a, 128, 129–34  
 Mainland's advice about, 127–8, 190ac  
 multiple look and, 122–6  
 'no significant difference' declaration, 119, 137  
 nonparametric tests of, 129  
 0.05 threshold of, 10b, 128, 137  
 P value, 130  
 parametric tests of, 129  
 publication decisions and, 21, 132–3  
 Pearson's definition of, 128  
 practical, 128  
 'significant difference', 128  
 in subclasses, 133–4  
 test, choosing a, 128–9  
 trial size and, 117f, 118f, 131–2  
 two-sided test of, 117f, 118f  
 validity of tests of, 50  
*see also* confidence intervals (limits); error, Type I; statistical reasoning
- Simes, R.J., 167, 191ac  
 Smithells, R.W., 137, 190ac  
 'snails', 149–50  
 Snow, John, 9b, 186ac  
 Socrates, 85b  
 Sonderegger, J.L., 159b  
 sortilege, 48, 56  
 spastic diplegia, *see* neurologic outcome  
 specificity, of a test, 95b  
 standards  
   criteria for trial deviations, 109  
   for observations, 94–5  
   for randomized trials, 180–81ap  
   standardized event rates, 101  
 statistical reasoning, 27–8  
   Bayes' approach, 135–6b, 147  
   historical roots of, 11, 139  
   'no significant difference', 119, 137  
   probable trend concept, 27  
   proof concept, 134–8  
   sample size, 97–8, 112–26, 130–32  
   'significance' declaration, 10b, 119, 123–5, 127–8  
   state of nature, 139, 141  
*see also* error; gambling; multiple look issue; probability; sampling, random
- Sterling, T.D., 132, 190ac  
 Steward, W.H., 157  
 stratification, 50–51  
 strawberry marks, 102–3  
 streptomycin, 11, 43–4  
 sulfapyrazole, 123  
 sulfoxazole, 46, 56  
 surgical treatment  
   for cancer, 58f, 103–4  
   prediction and, 142  
   for prevention of hemorrhage, 53–4  
   success rate of trials, 162f  
   variable outcome of, 58f  
 surveillance, informed, 167  
*see also* consent, informed  
 survival, *see* mortality; outcome  
 Susser, M., *vii*, 12b, 24b, 182fr  
 syphilis study scandal, 157  
 Szewczyk, T., 175ap
- target, *see* outcome, target events;  
 population ...  
 Taylor, C.E., 166  
 Teale, Edwin Way, 113b  
 Terry, T.L., 173ap  
 test, *see* hypotheses, test of; sensitivity;  
   'significance'; specificity  
 thalidomide disaster, 150  
 time, durations of  
   traps related to, 100–103  
   trial time, 89, 91  
*see also* life, life-table format;  
   observations, duration of  
 Tocqueville, Alexis de, 169b  
 transfer of neonates, 101  
 transfusion (exchange), 21  
 treatment, *see* interventions; medical  
   treatment ...; trials; *specific treatments*
- trials  
   in agriculture, 10–11b, 26  
   of ACTH, 59–60, 175ap  
   adaptive strategies for, 55, 125–6  
   of antibacterial treatments, 46, 56  
   biblical, 46b  
   children in, 166–7  
   community, 149  
   conditional, 68–9  
   conscription for, 165  
   cross-over, 67b, 68  
   of DES, 38  
   in developing countries, 166, 169  
   enthusiasm and, 53f  
   exclusions from, 107–8  
   explanatory, 29, 30  
   focused, 39–41  
   glossary in, 95  
   in highly fatal conditions, 114  
   injury in, 169  
   of intensive care, 87f, 99  
   irregularities in, 57, 69–70, 104–11  
   lost to follow-up in, 108f, 109  
   'masking' in, 62–3, 66–7  
   multicenter, *see* multicenter trials  
   'negative' results of, 59–60, 119–20, 132  
   numbers of, 131–2  
   of oxygen, *see* multicenter trials, of  
   oxygen and RLF; oxygen, trials  
   of ...  
   patients' attitudes, 164  
   patient recruitment, 41, 164–5  
   pilot, *see* pilot trials  
   planning period for, 106  
   play the winner design, 55  
   policing of, 110–11  
   of polio vaccine, 66, 165  
   practical limit of, 13, 107, 116  
   pragmatic, 29, 30, 109, 116, 137  
   precautions in, 104–11  
   quasi-experimental, 54b  
   randomized, *see* randomized clinical  
   trial format  
   realism in, 58, 106–7  
   reparation for injury in, 169  
   replication of, 148  
   risk limitation in, 13, 48, 52, 56  
   risks in, 114, 162–4  
   in scurvy, 7b  
   sensitivity of, 50  
   serial designs for, 68–9  
   series of, 62  
   size of, 97–8, 112–26, 130–32  
   of social effectiveness, 149  
   stopping rule, 112–26  
   stratification in, 50–51  
   of streptomycin, 11, 37, 43–4  
   success rate in, 162f  
   of sulfapyrazole, 123  
   of sulfoxazole, 46, 56  
   time, accounting of, 89–91  
   two-armed bandit design, 55  
   unwitting, 9b  
   veto options in, 167  
   volunteering for, 165  
   withdrawals from, 108  
*see also* Cancer Research Centre  
   (London); multicenter trials;  
   National Perinatal Epidemiology  
   Unit (Oxford); outcome,  
   'important difference' in  
 Truman, Harry, 138  
 tuberculosis, 11, 37, 43–4  
 Tukey, J.W., 39, 133, 187ac  
 two-armed bandit design, 55  
 Type I and II errors, *see* error
- United Kingdom  
 Bill to control experimentation, 157  
 Bills of Mortality, London, 24–6b  
 Cancer Research Centre (London), 184fr  
   cancer surgery in, 58f  
   cholera in London, 9b  
   evolution of trials in, 11  
   National Perinatal Epidemiology  
   Unit (Oxford), 183–4fr  
   oxygen treatment in, 18  
   scarlet fever in, 43f  
   tuberculosis in, 44f  
*see also* multicenter trials, of  
 streptomycin  
 utility, 144–6
- vaccine  
   reparation for injury, 169  
   trials, 66, 165  
 validity, *see* arithmetic; observations,  
   validity of; 'significance',  
   validity ...  
 values and judgments  
   choosing, 29, 30, 141, 146–7  
   conflicting, 147  
   professional autonomy and, 170  
 variability  
   cum approach to, 93f  
   in evaluations, 94  
   in interventions, 58–9  
   in manifestations, 92–6  
   numerical approach to, 26–8  
   in outcome, 97f  
   problems induced by, 22–6  
 Vesalius, Andreas, 2  
 Venn, John, 28, 31, 183fr  
 veto options, 167

vitamins and RLF, 16-17, 174-5ap  
volunteering in trials, 165

Wald, A., 125

'warfare', medical, 161b

Weaver, W., 18, 19, 186ac

Webster, C., 3, 185ac

Weinstein, M.C., 188ac

Wesley, John, 47b

withdrawals in trials, 108

Wohl, H., 93f, 189ac

Wolf, S., 66, 188ac

Youden, W.J., 82, 83f, 84f, 189ac

Zelen, M. 55, 116, 188ac